Latest news
-
05 June 2019 -
06 May 2019 Turning Point Therapeutics and Almac Diagnostic Services announce approval of an investigational device exemption for the companion diagnostic assay to the registrational TRIDENT-1 clinical study
Read more
-
18 April 2019 Almac Group Partner with Queen’s Researchers to pioneer potentially life-changing oesophageal cancer test
Read more
-
27 March 2019 Almac Group Launches Upgraded Version of claraT - A Unique, Software-driven Gene Expression Report
Read more
-
24 October 2018 TP Therapeutics and Almac Diagnostic Services Enter into Agreement to Develop Next-Generation Sequencing, Pan-Cancer Companion Diagnostic
Read more
-
19 October 2018 Almac Group Launches claraT - A Unique, Software-driven Gene Expression Report
Read more
-
11 October 2018 Almac Group Invests in Cutting Edge Next Generation Sequencing Capabilities for Bio Pharma Clients
Read more
-
10 October 2018 Almac Group Invests to Expand its Existing North Carolina Facility
Read more
-
16 April 2018 Almac Diagnostic Services Validates Illumina TruSight® Tumor 170 Cancer Mutation Panel for Prospective Testing in Clinical Trials
Read more